Rivista in lingua italiana
riservata ai Soci SISA
Ultimo numero:
Anno 15 • N.4/2024
Effect of apolipoprotein A-I on microbiota: a new mechanism of HDL-mediated atheroprotection?
Marco Busnelli
Abstract:
Background. The small intestine, together with the liver, is responsible for the synthesis of apoA-I, the most abundant protein of HDL. Moreover, the intestine harbors trillions of microbes, the so-called gut microbiota, that play a crucial role in host metabolic processes and, in particular, can influence cholesterol and bile acids metabolism. Interestingly, inflammatory conditions of the small intestine are associated with a downregulation of the APOA1 gene and lead to an altered microbiota composition.
Objectives. The proposed project is aimed at demonstrating, for the first time, that apoA-I can modulate intestinal homeostasis and microbiota composition and notably, that an apoA-I deficiency-driven dysbiosis can predispose to atherosclerosis development. This hypothesis is supported by two independent observations that have never been merged so far: i) apoA-I deficient mice have an altered microbiota composition, enriched in choline-degrading bacteria; ii) the gut microbiota can influence atherosclerosis development by processing dietary choline to trimethylamine, further metabolized to trimethylamine N-oxide (TMAO) by hepatic flavin mono-oxygenase.
Methods. The research strategy will be based on the use of both conventional and germ-free, atherosclerosis prone mice. In conventional genetically modified mice, lacking or overexpressing apoA-I, the effects of apoA-I and dietary choline on: i) atherosclerosis development; ii) TMAO production; iii) gut/liver homeostasis; iv) microbiota composition, will be evaluated. In addition, microbiota transfer from those mice to atherosclerosis-prone germ-free animals will be used to assess to what extent a deficit of apoA-I makes the gut microbiota harmful for atherosclerosis development.
Expected results. i) To demonstrate whether apoA-I deficiency promotes the presence of TMAO-producing bacteria in the gut that worsen atherosclerosis development; ii) to clarify how apoA-I modulates gut microbiota composition.
Presentazione del progetto vincitore della Borsa di Studio “Andrea Mezzetti” - 2016
Bologna, 1-3 dicembre 2024
Programma completo
Perugia, 7 Dicembre 2024
[continua a leggere]Ancona, 4-5 Ottobre 2024
[continua a leggere]Modena, 4-5 Luglio 2024
[continua a leggere]Rivista in lingua italiana
riservata ai Soci SISA
Ultimo numero:
Anno 15 • N.4/2024
Rivista Italiana della
Ipercolesterolemia
Familiare Omozigote
Anno 6 • N.1/2024
Nuovo sito dedicato al Progetto LIPIGEN
Progetto LIPIGEN - Vecchio portale
E' necessario essere loggati come utente
Lipigen per poter accedere alla pagina
PROSISA – PROject Statin Intolerance SISA
E' necessario essere loggati come utente
PROSISA per poter accedere alla pagina
Gruppo Interdisciplinare Lipoprotein Aferesi
(Accesso Gruppo GILA-Lipoprotein Aferesi)
E' necessario essere loggati come utente del Gruppo GILA per poter accedere
Gruppo Interdisciplinare Lipoprotein Aferesi
(Documentazione ad accesso libero)
Pagina informativa per medici e pazienti